Positioning Acomplia: Has the Drug Arrived Before the Disease?
Sanofi-Aventis is the envy of many as it awaits approval for fat-busting metabolic syndrome drug, Acomplia. But obesity is rarely reimbursed; metabolic syndrome still undefined.
You may also be interested in...
GlaxoSmithKline went out on a limb by paying $720 million for Sirtris' relatively untested enzyme technology. How FDA evaluates the first-in-class therapy will determine whether GSK was pound wise or pound foolish. Two former FDA reviewers weigh in on how the company can make the most from its investment.
Israel's Obecure is investigating the potential of a marketed compound, betahistine, in obesity. It's hoping this repositioning approach will both accelerate timelines and help it overcome growing drug safety hurdles.
Rimonabant had all the early signs of a mega-blockbuster. But behind that shiny veneer was a drug with a serious risk profile-one that mimicked the suicidality rates of the SSRI class. That made rimonabant an enormous red flag for FDA reviewers. Why didn't Sanofi-Aventis see it coming?